Data collected by Wang et al. [34] showed that eight weeks after the second injection of anti-SARS-CoV-2 mRNA vaccine, volunteers had significantly higher levels of anti-S IgG and IgM than a cohort of patients who had recovered from COVID-19 (assayed at 1.3 and 6.2 months after infection). The gene discussed is CD40LG; the disease is COVID-19.